Supporting information

Matrix Metalloproteinase Responsive Nanoparticles for Synergistic Treatment of Colorectal Cancer via Simultaneous Anti-Angiogenesis and Chemotherapy

Leilei Shi,[†] Yi Hu,[†] Ang Lin,[§] Chuan Ma,[‡] Chuan Zhang,[†]* Yue Su,[†] Linzhu Zhou,[†]

Yumei Niu,^I* and Xinyuan Zhu[†]*

[†] School of Chemistry and Chemical Engineering, State Key Laboratory of Metal

Matrix Composites, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai

200240, People's Republic of China

[‡] School of Dental Medicine, Shanghai Jiao Tong University, 227 South Chongqing Road, Shanghai, 200025, P. R. China

§ Department of Medicine, Immunology and Allergy Unit, Karolinska Institute,

Stockholm, SE 17176, Sweden

¹Department of Endodontics, The First Affiliated Hospital of Harbin Medical

University, 143 Yiman Street, Harbin 150001, P. R. China

*Corresponding author. E-mail: chuanzhang@sjtu.edu.cn, yumeiniu@163.com, xyzhu@sjtu.edu.cn; Telephone: +86-21-54746215; Fax: +86-21-54741297.

Table of Content

1.	FTIR spectrum of mPEG-peptide	S3
2.	The chromatogram of peptide and mPEG-peptide	. S4
3.	The standard curve of CPT and sorafenib.	.S5
4.	3D images of photoacoustic imaging.	. S6
5.	TEM image of Cy5.5 loaded nanoparticles	. S7
6.	The calculated combination index (CI) value	.S8




Figure S1. FTIR spectrum of mPEG-CPLGLAGG.





Figure S2. The chromatogram of mPEG-CPLGLAGG and CPLGLAGG.






Figure S3. The standard curve of CPT (upper) and sorafenib (down) for determining drug loading content. X-axis indicates concentration (μg/mL), Y-axis indicates CPT and sorafenib absorbance peak area, respectively.




Figure S4. 3D images of *in vivo* oxyhemoglobin and deoxyhemoglobin PA signal change.




Figure S5. TEM image of Cy5.5-loaded nanoparticles. Scale bar is 0.5 μm .

Combination Index (CI) of CPT and sorafenib mixture




Figure S6. The calculated combination index (CI) value of drug mixture (CPT and sorafenib) at different inhibition rate.